Tawbi et al., in a cohort study (SARC028), investigated the use of pembrolizumab (anti-PD-1) in 42 STS (leiomyosarcoma, dedifferentiated liposarcoma, undifferentiated pleomorphic sarcoma and synovial sarcoma) and bone sarcoma [100]. This evidence concerns the gene PDCD1 and bone sarcoma.